VibroSense Dynamics AB (VibroSense) adds a new application to its product VibroSense Meter® II, which provides support for Diabetes Foot Screening. The new application is a result of 5 years of clinical studies involving adult patients with type 1 diabetes and is expected to be available for commercial launch in the fall 2020.
The screening function of VibroSense Meter® II within HAVS (vibration damage), was launched in the fall 2019 and is an application to detect early nerve damage in hands caused by vibrating tools. Research at Skåne University Hospital have shown that the method can also favorably be used to early detect nerve impairments of feet on people with type 1 diabetes. The result of a Diabetes Screening is reported in three gradings: Normal, Suspected, or Significant deviation in relation to a reference group, consisting of 1,100 healthy individuals aged 8 to 80 years. Suspected or Significant deviation indicates that possible nerve damage may exist. The screening method gives the healthcare sector access to a new tool that offers reliable and repetitive measurement to detect early nerve damage caused by diabetes.
- The launch of the new application Diabetes Screening, is part of VibroSense's long-term strategy to add new applications to the product, as soon as new clinical data becomes available from the company's research partners. After completing a 5-year prospective study involving adults with type 1 diabetes, VibroSense has now compiled clinical data that is the basis of the new screening module. The screening takes less than 10 minutes and gives health care professionals in diabetes a reliable result, saving a lot of time. We are very pleased to offer a new and effective instrument, as a complement to today's existing tools, many of which are over 50 years old, says Hans Wallin, CEO VibroSense Dynamics AB.
VibroSense Dynamics AB Hans Wallin, CEO VibroSense Dynamics AB, Phone: +46 40 88 026 E-mail: firstname.lastname@example.org www.vibrosense.com
About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (public) manufactures and develops efficient systems to support early detection and diagnosis of sensory neuropathy, i.e. disease of large nerve fibres and nerve trunks in e.g. legs and arms. Our vision is that the VibroSense Meter shall be the golden standard instrument for neurological examinations to assess sensory neuropathy and help to improve life conditions for patients having a risk of getting nerve injuries.